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Abstract  Peritoneal  carcinomatosis  refers  to  a  shedding  or  tumor  that  spreads  to  the  periton-
eal serosa  and  structures  of  the  abdominal  cavity.  It  is an  entity  with  a  poor  prognosis.  Several
conditions  can  cause  this,  the  most  common  being colon,  rectum,  ovary,  stomach  or  appendix
cancers,  including  peritoneal  pseudomyxoma,  among  others.  The  abdominal  cavity  invasion  is
considered  a  clinical  stage  IV.  For  a  long  time  life  expectancy  of this entity  was  very  short.  With
the advent  of  meticulous  techniques  in cytoreductive  surgery  (CRS)  and  hyperthermic  intraperi-
toneal chemotherapy  (HIPEC)  the  prognosis  of  patients  has  changed.  In  some  conditions,  these
procedures  are  standard  treatments.  CRS  is  a  very  important  prognostic  factor;  leaving  a  less
residual  disease  in  the patient,  the  evolution  will  be better.  The  HIPEC  starts  immediately  after
the surgical  event.  The  hyperthermia  increases  the  cytotoxic  effect  of  antineoplastic  drugs.
Numerous studies  have  appeared  in  medical  literature  wherein  the  clear  improvement  in  sur-
vival of  the  affected  population  is demonstrated.  It  is  essential  that  a  multidisciplinary  team
participates  in  the  decision  for  the  best  treatment  option  and  the  maximum  clinical  benefit  of
the patients.
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Introduction
Peritoneal  carcinomatosis  (PC)  refers  to  the shedding,
implantation  and  dissemination  of  a  tumor,  either  localized
or  massive,  to  the peritoneal  serosa,  as  well  as  the adjacent
structures  of  the  abdominal  cavity.  Its  presence  indicates
a  clinical  stage  IV.  It is  usually  associated  with  gynecologi-
cal  tumors  and  tumors  of  the digestive  tract.1--3 The  exact
incidence  of  PC as  a  primary  site  and as  a recurrent  site
is  not  known  with  any certainty,  since  most  analytic  and
imaging  studies  used to  monitor  different  pathologies  do
not  allow  for  the detection  of  said  dissemination  in ini-
tial  studies.  Numbers  vary  according  to  the  pathology;  the
most  representative  is  colon  cancer.  Estimations  suggest
that  initial  recurrence  in the  peritoneum  after a surgery
with  curative  intentions  is  10--20%.  Peritoneal  dissemination
occurs  in  40--70%  of  total  recurrences  and  only  5--8%  present
a disease  strictly  confined  in the  peritoneum.  Considering
all  patients  with  the  inclusion  of  all  original  pathologies,
medical  literature  shows  that  15%  of  patients  arrive  with
PC  at  first  and  35%  die  of  intraperitoneal  recurrence.4 Up
to  a  few  years  ago,  this entity  had  had  an  adverse  prog-
nosis  with  a  fatal  outcome  within  months.5 However,  the
evolution  of  the  disease  can be  changed  with  an excel-
lent  full  cytoreductive  surgery  (CRS)  and  the emergence  of
intraperitoneal  chemotherapy  (IPCT).  Life  expectancy  used
to  be  very  limited  and dependant  on  the  base  pathology:
between  3 and 6  months  for  gastric  base  PC,4,6 11--21  months
for  colon/rectal  PC and  14--24  months  for  ovarian  PC,  on
average.  The variant  linked  to  peritoneal  pseudomyxoma
has  shown  better  survival  rates,  due  to  the  tumor’s  biology
and  its  response  to  multimodal  treatment.  In  all  the previ-
ously  mentioned  cases,  CRS  and IPCT  have  increased  these
numbers.
Today,  peritoneal  affection  is  being  considered  as  a
locoregional  dissemination,  thus  generating  the idea  of
performing  metastasectomies  in  said  entity  with  the  pur-
pose  of  leaving  patients  disease-free.  In  the  late  80s,
Dr.  Sugarbaker  developed  a treatment  with  a  radical
approach,  consisting  of  a  combination  of  CRS  and  IPCT,
the  latter  in its  early  post-operative  modality  (EPIC  early
postoperative  intraperitoneal  chemotherapy), and  in cases
requiring  hyperthermia  (HIPEC  hypertermic  intraperitoneal
chemotherapy).  The  key  objective  of  the radical  approach
is  to  completely  eliminate  the visible  disease  through  CRS
and  EPIC  or  HIPEC,  and  to  eradicate  non-visible  tumor
residues.  CRS  ought  to  be  thorough  in  order  to  release  adher-
ences,  in  addition  to  retreating  tumor  implantations,  so  that
chemotherapy,  once  administered,  is  distributed  homoge-
neously  amongst  the intra-abdominal  organ surfaces.7,8
During  the  last decades,  CTIP  and  CRS  have been sig-
nificantly  revolutionized,  thus  resulting  in favorable  results
in  patient  survival  rates,  which  had  not been  achievable  in
previous  years.
Physiopathology and  the  plasmatic peritoneal
barrier
Cancers  in  the  abdomen  spread  via three  different  routes:
haematogeneous,  lymphatic  and  celomic.  The  latter  led to
the  hypothesis  that in eliminating  this  type  of  dissemination,
the  risk  of  extension  of  the  disease  would  decrease  and
free-of-recurrence  survival  rate  would  increase.  Periton-
eal  liquid  goes  from  the pelvis  to  the  diaphragm  and  is
defined  by  the  reflections  of  the peritoneum.  Intraperi-
toneal  seeding  through  ascites  is  one  of the most  significant
forms  of  peritoneal  metastasis  and  the leading  cause  of
PC.  Regardless  of  the dissemination  mechanism,  tumor  cells
spreading  to  the  peritoneal  cavity  do  so  in  different  ways:
through  gravity,  peristalsis  and/or  negative  pressure  of  the
diaphragmatic  muscles.2,9 Once  the tumor  cells  adhere,  they
penetrate  the mesothelial  monolayer  and initiate  the  PC
process.  The  peritoneal  tissue  provides  a source  that  is  rich
in nutrients,  growth  factors  and  chemokines,  leading  to  a
favorable  environment  for  tumor  cell  proliferation.9 The
plasmatic  peritoneal  barrier  maintains  a  positive  gradient
of  chemotherapy,  causing  medications  with  a high  molecular
weight  to  remain in the abdominal  cavity  for  a longer  period
of  time,  allowing  for  a  greater  exposure  of  tumor  cells  to  the
medications,  compared  to  the intravenous  route.1,4,10
Diagnosis
Different  techniques  are used  in  diagnosis,  such  as  imaging
studies  like  ultrasounds,  CAT  scans,  NMR  scans and  PET/CT
positron  emission  tomographies  with  fluorodeoxyglucose 18F.
Nevertheless,  these studies  have  their  limitations.  They are
usually  used  more  in  staging  and  for  non-resectable  disease
assessment.4 CAT  scan  sensitivity  for  PC  diagnosis  ranges
between  41  and  93%  with  a specificity  between  79  and
96%.  CAT  scans can  prove  previously  established  imaging
patterns,  including  the ‘‘omental  cake’’  which  represents
fat  implants,  thickening  and heterogeneity,  subcapsular
implants,  nodular  lesions,  associates  and  mesenteric  fat  tis-
sue  tumor infiltration.2
There  are  different  systems to  measure  PC.  The  most uti-
lized  is  the  peritoneal  carcinomatosis  index  (PCI),  which is
based  on  the peritoneal  nodules’  size and  quantitative  dis-
tribution.  The  abdominal  cavity  is  divided  into  13  regions
and  the  volume  of  the disease  is  determined  in  every  region
(Fig.  1).  After a thorough  surgical  inspection,  the  extension
of  the disease  is measured  in relation  to  every  region,  assign-
ing them  a number  (score  from  0 to  39). PCI  has  a prognosis
value  in addition  to  estimating  the possibility  of full cytore-
duction.  A series  published  a survival  rate  at 5 years  of
50%  for PCI  < 10,  20%  for  PCI  10--20  and  0%  for  PCI  > 20.5,11,12
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Figure  1  Abdominopelvic  regions.  Peritoneal  carcinomatosis
index.
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Sugarbaker  recommends  a  palliative  management  with  a  PCI
greater  than  20.13 Some  groups  use  a  PCI  > 26  as  a reference.
Surgical  treatment
The  decision  of  the oncological  surgical  treatment  type
depends  on  the  anatomic  location  of  the  malignancy  as
well  as  its  biological  behavior.  Cytoreductor  management
may  require  6 types  of peritonectomy  procedures,  used  to
resect  cancer  from  all  abdominal  surfaces.  These  are  the
types:  (1)  Pelvic  peritonectomy,  with  or  without  the exci-
sion  of  the  sigmoid  colon or  rectum,  mesorectum,  uterus
and  annexes.  (2) Major  omentectomy,  with  or  without  a
splenectomy,  and  with  or  without  a right  colectomy.  (3)  Left
hemidiaphragm  peritonectomy.  (4)  Right  hemidiaphragm
peritonectomy,  with  or  without  a  Glisson  capsule,  and  with
or without  a sub-hepatic  peritonectomy.  (5)  Minor  omentec-
tomy  with  a cholecystectomy,  and  (6) Gastrectomy  and  other
intestinal  resections.7 Major  omentectomy,  oophorectomy
(in  post-menopausal)  as  well  as  cholecystectomy  will  always
be  carried  out,  the  latter  with  the  purpose  of avoiding
post-operative  complications  related  to  chemotherapy.  Peri-
tonectomy  procedures  allow  us to  accomplish  the  objective
of  removing  all  visible  disease,  with  acceptable  post-surgical
complications,  reporting  morbidities  in 25%  and mortality
in  1.5%.12 CRS  can  be  evaluated  using  the Sugarbaker  tech-
nique,  according  to  the residual  disease  classification  after
cytoreductive  surgery:  CC0  defined  as  non-visible,  CC1,  per-
sistent  nodules  under  0.25,  CC2,  nodules  between  0.25  and
2.5  cm  and  CC3,  nodules  over 2.5  cm.14 The  important  thing
is  to  accomplish  full  cytoreductive  surgery,  determined  as
CC0  or  CC1.15,16 CRS  residual  disease  plays  a  prognosis  role
regarding  survival  rate.  At  5 years,  it is  35%  with  CC0  and
CC1  versus  0% with  CC2  and  CC3.12 Recently  Esquivel,  et  al.
reported  the role  of  laparoscopy  for  the completion  of  CRE
with  HIPEC  in  14  patients.  CC0 was  accomplished  in 13
patients,  10  (77%)  via  laparoscopy  and  3  (23%) via open
surgery.  However,  they were  well-selected  patients,  with  a
low  tumor  load  and  without  intestinal  involvement.17
CTIP
As  its name  states,  it is  about  administrating  chemother-
apy  agents  via intraperitoneal.  There  is  evidence  that  some
drugs  administered  in large  amounts  via  intraperitoneal
maintain  a  significantly  higher  concentration  in the perit-
oneal  area  compared  to  plasmatic  concentration.  A  large
concentration  of  drugs  offers a biochemical  advantage  in the
treatment  of  patients  with  microscopic  neoplastic  disease
in  the  peritoneal  cavity.18 Very  positive  results  with  the  use
of  chemotherapy  in patients  with  peritoneal  carcinomato-
sis,  sarcomatosis  and mesothelioma  have  been  reported.
The  most  commonly  used  drugs  in the CTIP  scenario  are
oxaliplatin,  irinotecan,  adriamycin,  cisplatin,  mitomycin,
paclitaxel  and  gemcitabine.  CTIP  causes  local  and  sys-
temic  toxicity,  since  the  drugs  will  eventually  enter  the
blood  stream.1 Once the drugs  are administered  via  IP, they
destroy  tumor  cells  directly,  as  well  as  decrease  cells  of the
inflammatory  process,  altering  the ability  to  withstand  an
infectious  process.  Thus,  sterility  and  asepsis  during  the full
procedure  are  imperative.  As  previously  mentioned,  CTIP
can  be administered  in two  different  ways,  EPIC  and HIPEC,
both  preceded  by  CRS.  The  difference  between  them  is  that
catheters  are left  for  the administration  of CT  in the  first
one, which  is  usually  performed  in 5 days,  and  the second
one  is  a single  postoperative  procedure.  Today,  the  most
utilized  is  HIPEC.  There  are studies  where  both  HIPEC  and
EPIC  treatment  modalities  are  combined,  which  has  not  gen-
erated  benefits  in survival  rates,  though  it has  generated
greater  toxicity.19
HIPEC
The  connection  between  chemotherapy  and hyperthermia
is  what’s  known  as  HIPEC.  It  is  limited  to  a  single  treat-
ment  session.  Simultaneous  use  of HIPEC  with  intravenous
chemotherapy  (bidirectional  chemotherapy)  improves  sur-
vival  rate  results  in some  types  of  PC.  The  interest  on
hyperthermia  has  focused  on three  fundamental  aspects:
(1)  increased  temperatures  themselves  have  a  cytotoxic
effect,  (2)  hyperthermia  increases  the inactivation  by  radi-
ation  rate  and more  importantly  (3)  the cytotoxic  effect
of  chemotherapy  agents  is  increased  with  the elevated
local  temperature.20 Hyperthermia  of  40--42 ◦C, along with
chemotherapy,  help  drugs  penetrate  malignant  tissue  (from
3  to  6  mm),  thus  increasing  the cytotoxic  effect.2,4 From  the
first  studies  within  the use  of  CTIP literature,  is  phase  I,
which  researched  the role  of  5-fluorouracil.  Said  drug  was
administered  through  dialysis  catheters  to  individuals  with
tumors  limited  to  the peritoneal  cavity,  the patients  devel-
oped  the  same  adverse  effects  caused  by  that  of  intravenous
administration,  two  patients  displayed  a clinical  response,
concentrations  of peritoneal  liquid  were  measured  and  they
decreased  in the first  order  with  an average  lifespan  of  1.6  h.
In  4 h 82%  of  the IP  drug was  absorbed,  and the  medication’s
plasmatic  levels  began to  rise  after  30--45  min.  There  was
a  significant  difference  between  intraperitoneal  and plas-
matic  levels;  concentrations  in peritoneal  liquid  were  298
times  greater  at 4 h compared  to  the levels  in blood.21 In
the late  80s,  Sugarbaker  proved  that  it was  possible  to  keep
patients  with  pseudomyxoma  peritonei  free  of  disease  with
cytoreductive  surgery  and  the  administration  of chemother-
apy  with  5-fluorouracil  and  mitomycin  C.22 Other  studies
have  used other  drugs  which  have  proven  to  be compatible
with  hyperthermia,  these  being  oxaliplatin,  mitomycin  C,
cisplatin,  doxorubicin,  paclitaxel  and  irinotecan.23,24 Intra-
abdominal  temperature  should  not  exceed  43◦ in order  to
avoid  adverse  effects  harmful  to  the tissue,  such  as  intesti-
nal  perforation.
Patient selection for  CTIP
In the past,  many  patients  were  treated  with  HIPEC  despite
being  CC2  and CC3,  resulting  in the  absence  of expected
benefits.  Residual  disease  is  an  important  criterion  in  patient
selection  for  this  management  protocol.  The  extent  of  the
disease  at  the time  the patient  begins  treatment  will  corre-
late  to  the  eventual  results.  Patient  selection  should  be  done
early,  and  it is  important  to  have a  multidisciplinary  team
participating  in the process.  Today,  there  are  4  major  points
to  take  into  account  when  selecting  patients:  the invasive
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Table  1  Indications  for  the  combined  treatment  of  CRS  and
CTIP.
1)  Malignant  ascites
2) Peritoneal  pseudomyxoma  after  a  CRS
3) Peritoneal  mesothelioma  after  a  CRS
4)  Primary  colon  and  rectal  cancer
- Peritoneal  seeding  of  limited  distribution  and  small
volume
- Perforated  colon  cancer
- Colon  cancer  involving  adjacent  organs
- Colon  cancer  disseminated  to  the  ovaries
- Colon  cancer  with  a  positive  cytology  IP
- Tumor  rupture  at  a  primary  resection
5)  Recurrent  colon  and  rectal  cancer  with  carcinomatosis
-  Peritoneal  seeding  of  limited  distribution  and  small
volume
- Krukenberg
-  Tumor  rupture  at  a  resection  of  a  recurrence
- Completed  ebulking  of  a  recurring  disease  at  more
than  one  site
6)  Recurring  ovarian  cancer  with  limited  dissemination  to  the
peritoneum
- Prolonged  interval  free  of  disease  between  initial
treatment  and  recurrence
- Limited  or  no options  for  chemotherapy  via  IV
7) Primary  gastric  cancer  with  limited  peritoneal  implants
after a  complete  resection  of  both
8)  Peritoneal  sarcomatosis
- Sarcomatosis  following  CRS
- Primary  abdomino  pelvic  sarcomatosis  with  doubtful
resection  margins
- Primary  abdomino  pelvic  sarcomatosis  with  tumor
rupture  at resection
nature  of the  disease,  previous  CATs, ICPs and  the full  CRS
score.2,25
Indications  for  CRS and CTIP  are  shown  in  Table 1.
Patients  with  a good  functional  state,  a  low volume  perit-
oneal  disease  and  an absence  of  extra-abdominal  metastasis
are  more  commonly  benefited  by  the  treatment.1,26 Patients
admitted  to  CRS and  HIPEC  must  have  a leukocyte  count
of  >3000/mm3, polymorphonuclears  of  >1500,  platelet
count  of  >100,000/mm3,  normal  creatinine  or  calculated
depuration  at  >50  ml/min  and  a signed  consent  form.27
Contraindications  for HIPEC  are age  >70 years,  major  comor-
bidities,  a  reaction  to  chemotherapeutics,  malnutrition,
extra-abdominal  metastasis,  non-rescuable  hepatic  metas-
tasis,  massive  retroperitoneal  disease  or voluminous  lymph
node  involvement  and  signs  of intestinal  occlusion.4 Con-
cerning  sarcomatosis  treatment  by  GIST and  round  cell
tumors,  studies  are  limited  and  treatment  with  HIPEC  is  not
indicated.13
Procedure
A  strict  monitoring  of  the patient’s  vital signs is required
(temperature  ought  to  be  measured  with  an esophageal  tem-
perature  probe)  and  a  proper  monitoring  of  diuresis.  After
a  full  resection  of  tumor  implants  and  the liberation  of
the loops  removing  fibrin  bridges  and  adherences,  place-
ment  of  administration  tubes  (at  least  a perfusion  tube)
and  drainage  tubes  takes  place  prior  to  HIPEC.  In  addition,
three  temperature  sensors  are  placed  in the  abdominal  cav-
ity  (superior,  middle  and  inferior).  Before  initiating  HIPEC,
the chemotherapy  complement  being used  is  administered
intravenously  (bidirectional  chemotherapy).  There  are  two
techniques  to  perform  HIPEC;  open  (coliseum)  and closed.
The  most  utilized  technique  is  coliseum  (Fig.  2).  There  are
no  studies  proving  that  one is  better  than the other.  An  extra-
corporeal  circulation  machine  is  used  for  HIPEC  treatment
(Fig.  3),28 which  previously  heats  an isotonic  dialysis  solution
or  a glucose  solution  at 1.5%,  minimum  of 2  l,  at 40--42 ◦C.
Once  the temperature  is  reached,  the  abdominal  cavity  is
filled  with  the previously  preheated  solution.  This  solution
is  distributed  evenly,  trying  to  reach the desired  tempera-
ture  homogenously  in  the abdominal  cavity,  and  once  this
is accomplished  the  administration  of  chemotherapy  takes
place,  manipulating  the  influx  tube  as  well  as  the  tissue  and
intestinal  loops  in order  to  continue  with  the uniformity  of
intra-abdominal  temperature.  After  the time,  which  can be
between  30  and  120  min,  is  completed,  the cavity  is  emp-
tied,  the  abdomen  is  reassessed  in order  to  find  tissue lesions
or  bleeding  and  when the  procedure  is  finished,  the  circuit
Figure  2  Coliseum  technique,  with  placement  of  influx  and
drainage  tubes  and temperature  sensors.
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Figure  3 Hyperthermic  recirculation  machine.
is  retracted,  drainages  are  placed  and closure  by  planes  is
performed.13,27
Scientific evidence  of  the  use of CTIP and
HIPEC
Over  the  last two  decades,  combined  treatment  with  CRS
and  HIPEC  has  modified  therapeutic  treatment  for  patients
with  malignancies  on  the  peritoneal  surface,  becoming
the  gold  standard  for the  management  of  some  of  them.
Accepted  pathologies  for  this  are:  peritoneal  pseudomyx-
oma,  mesothelioma,  colon  cancer,  ovarian  cancer  and
gastric  cancer.  The  benefit  of  CTIP  is  shown  in Table 2.  Cardi
et  al.,  recently  published  the use  of  CRS and  HIPEC  in  non-
conventional  pathologies  from  a  series  of  253  patients,  28
of  them  with  a differential  diagnosis  of  sarcoma,  GIST,  and
different  types  of  cancer  such  as  of  the  small  intestine,
pancreas,  breast,  bladder,  lung and  uterus,  which showed
a  mean  overall  survival  (OS)  of 56  months  and  OS  at 5 years
of  40.3%  with  a difference  amongst  patients  with  CC0  and
CC1  (52.3  versus  25.7%).29 The  two  key  components  in the
treatment  of  this pathology  are CRS  and CTIP.  A systematic
review  of  the  efficiency  of  cytoreductive  surgery  and the
use  of CTIP  in peritoneal  pseudomixoma  was  published  by
Yan  et al.,  In  this  review,  survival  rate  means  of 51--156
months  are  shown,  OS at 1, 2, 3 and  5  years  was  80--100%,
76--96%,  59--96%  and 56--92%  respectively,  with  a  global  mor-
tality  rate  of  0--18%.30 Yonemura  et  al.,  studied  patients  with
gastric  cancer  who  underwent  CRS  and  HIPEC,  reporting  sur-
vival  rates  at 5 years  of  61% compared  to  42%  from  surgery
alone.31 Regarding  colon  cancer,  an improvement  has also
been  proven  in OS  (P  <  0.0001).32 Verwaal  et al.,  randomized
patients  with  colon  and rectal  cancer  to  receive  systemic
chemotherapy  with  or  without  palliative  surgery  versus  CRS
with  HIPEC,  proving  a  benefit  in mean  survival  rates  in
favor  of CRS  with  HIPEC.  In  a  follow-up  at 21.6  months,
OS mean  was  22.3  versus  12.6  months  (p  = 0.032),  in  a sub-
group  analysis,  researchers  showed  that  patients  with  0--5
affected  regions  have  better  results  compared  to  patients
with  6  or  7 affected  regions  (OS  mean  >29  versus  5.4  months
{p  <  0.0001},  respectively).  Reported  toxicities  of  3rd and
4th  degree  are  low;  amongst  the  most  common  are  leuco-
penia  (15%),  fever  (6%),  bleeding  (8%),  and  gastrointestinal
fistulas  (15%).33 In 2008,  Elias  et al.,  reported  the  benefit  of
chemo-hyperthermia  with  oxaliplatin  in patients  with  PC of
colorectal  origin,  reporting  a  survival  rate  of  63  months,  and
a  survival  rate  at 5 years  of  51%.34 Hompes  et  al.,  reported
morbidity  and  mortality  rates  with  the  use  of  CRS and HIPEC;
mortality  rates  at 30  days  was  0%,  the rates of  complications
of  any  degree  was  52%,  anastomosis  leakage  10.4%,  and
bleeding  6.3%,  with  an  average  hospital  stay  of  20  days.  With
a  follow-up  at 22.7  months,  he  reported  a OS of  97.9  and
88.7%  at 1 and  2  years,  respectively.  Disease  free  survival
(DFS)  of  65.8  and 45.5%  at 1 and  2  years,  respectly.35 Mor-
tality  rate  for this treatment  has  been  reported  at  8%.33,36
Glehen  et al.,  conducted  a multi-institutional,  retrospective
study,  which  included  506  patients  with  colon  and  rec-
tal  cancer.  Morbidity  rates  were  22.9%  and mortality  rates
were  4%,  patients  who  underwent  CRS reached  OS  means  of
32.4  months  compared  to  8.4 months  for  those  patients  for
whom  CRS  was  not  possible.37 A meta-analysis  published  by
Huo  et al.,  analyzed  treatment  with  CRS  and  HIPEC  versus
CRS  and intravenous  chemotherapy  in patients  with  primary
and  recurrent  epithelial  ovarian  cancer.  In  this  study,  an
improvement  in survival  rate  in favor  of CRS and  HIPEC  is
proven.38 Barrios,  et  al.  reported  618 patients  with  CRS  and
HIPEC,  561  (91%) with  CC0-1 and 57  non-optimal  surgeries
(9%).  Out  of  the patients  with  CC0-1,  44%  had  colon  can-
cer,  20%  had  peritoneal  pseudomixoma,  15%  had  recurrent
ovarian  cancer,  5% had  gastric  cancer,  4% had cancer  in the
appendix,  3% had mesothelioma,  2.3%  had  rectal  cancer,  and
6.7%  had some other  type  of  cancer.  Survival  rate  mean  was
60.2  months  for the group  in general,  51.2  months  for  the
colon  cancer  group,  45.4  months  for  the recurrent  ovarian
cancer  group,  29  months  for  the  gastric  cancer  group,  36
months  for  the  appendix  cancer  (non-pseudomixoma)  group,
46  months  for the mesothelioma  group,  and  24  months
for  the  rectal  cancer  group.  Moreover,  the global  compli-
cation  rate  was  27.5%,  amongst  the most frequent  were
central  line  infections  (3.8%),  non-focal  fevers  (3.8%),  uri-
nary  tract  infections  (2.7%),  and  haemoperitoneums  (2.1%).
Re-interventions  were  necessary  in 3.5%  and the mortal-
ity  rate  was  0.1%.39 Today,  the  COLOPEC  protocol  is  in  the
works.  This  protocol  will  evaluate  PC  prevention  with  HIPEC
in patients  with  high-risk  colon cancer.27
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Table  2  Scientific  evidence  of  the  use  of  CTIP  and  HIPEC.
Reference  Base  pathology  Treatment  GSR
Cardi  et  al.29 Sarcomas,  GIST,  cancer  of  the
small  intestine,  pancreas,
breast,  bladder,  lung  and
uterus
CRS  + HIPEC  Mean,  56  months
At  5 years,  40.3%
CC0  52.3%
CC1  25.7%
Yan et  al.30 Peritoneal  pseudomyxoma  CRS  and  CTIP  Mean,  51--156  months
Yonemura et  al.31 Gastric  cancer  CRS  + HIPEC  At  5 years,  61%
Verwaal et al.33 Colon  and  rectal  cancer  CRS  + HIPEC  vs.  Systemic
chemotherapywith/out
surgery
Mean,  22.3  vs.  12.6
months
Elias et  al.34 Colon  and  rectal  cancer CRS  + HIPEC Mean,  63  months
Hompes et  al.35 NR CRS  + HIPEC At  2 years,  88.7%
Glehen et  al.37 Colon  and  rectal  cancer  CRS  + HIPEC  vs  no CRS  Mean,  32.4  vs.  8.4  month
Huo et  al.38 Ovarian  cancer  CRS  + HIPEC  vs  Systemic
CT  + surgery
NR
Barrios et  al.39 Colon  cancer,  peritoneal
pseudomyxoma,  recurrent
ovarian  cancer,  stomach,
appendix,  mesothelioma  and
colon  cancer
CRS  + HIPEC  Mean,  60.2  months
Some  positive  prognosis  indicators  are CRS,  lymph  node
invasion,  limited  extension  of  PC,  age  under 65  and the  use
of  adjuvant  chemotherapy.4,37
Quality  of  life  prior  and  subsequent  to  the CRS  and HIPEC
procedures  was  assessed  by  a  study.  The  study  showed  a
physical  activity  and  functionality  decrease  in post-surgery;
however,  the  patients  returned  to  normal  after  3 months  of
treatment.40
Neoadjuvance in CRS with  HIPEC
The  optimal  sequence  of  systemic  chemotherapy  in CRS
radical  treatment  with  HIPEC  is  not  fully  defined.  There
are  few  studies  for  neoadjuvance  and evidence  is  discord-
ant.  Kuijpers  et  al.,  proved  that  there  is  no difference  for
OS  and  DFS  between  adjuvance  and neoadjuvance.41 Some
advantages  that neoadjuvant  chemotherapy  may  have  are:
undetectable  systemic  disease  treatment,  biological  tumor
behavior  assessment  and reduction  in the  tumor  load.  Some
probable  disadvantages  are  the possible  toxicity  in post-
surgery,  progression  of  the  disease,  difficulty  to  stage  the
disease  and difficulty  to  assess  the  response  to  chemother-
apy.  CRS  and HIPEC  are  conducted  4  weeks  after  the  last
chemotherapy  dose  and  6  weeks  if bevacizumab  was  used.37
Conclusion
CRS  and  HIPEC  have  revolutionized  the treatment  of  patients
with  PC,  reaching  better  results  in  global  survival  and free-
of-disease  rates.  Patient  selection  is crucial  and  should  be
conducted  by  a  multidisciplinary  team  in order  to achieve
better  results.  It  is  imperative  to  accomplish  full  cytore-
ductive  surgery  in the management  of  these  patients,  thus
assuring  the  best  prognosis.  CRS  and  HIPEC  can be consid-
ered  the  new  golden  standard  in the management  of  patients
with  PC.
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